Determination of Amifostine Levels During Radiation Therapy

Completed

Conditions studied: Cancer

In brief

Currently, there are no published methods for easily determining the level of amifostine in the blood or saliva. A method has been developed within the Department of Radiation Oncology by Drs. Douglas Spitz and Gurminder Sidhu, within the Spitz Lab. This method has been tested using both animal sampling and expired blood (obtained from DeGowin blood center) mixed with amifostine. If the method proves successful, it could then be used as a tool to quantify blood and salivary amifostine levels and possibly correlate them to treatment efficacy or limiting adverse events using amifostine. A better method of treatment, either increasing the efficacy of amifostine or reducing its unwanted side effects, could then be developed.

Key facts

Study ID

NCT00286611

Run by

University of Iowa

People needed

13

Starts

2004-10-01

Expected to finish

2008-05-01

Last updated by the study team

2008-06-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to understand and willingness to sign a written informed consent document.
• Receiving radiation treatment at University of Iowa Hospitals and Clinics.
• Voluntarily elected to receive amifostine during treatment

You may not qualify if…

• none

Where it is running

• University of Iowa Department of Radiation Oncology — Iowa City, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.